Stablecoin Development (SDEV) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Stablecoin Development (SDEV) over the past year, losing 36.4% versus a loss of 76.1%. Zhengye Biotechnology is the larger company by market cap ($82.0 million vs $79.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDEV | ZYBT |
|---|---|---|
| Share price | $1.54 | $1.73 |
| Market cap | $79.70M | $81.99M |
| 1-day change | -22.61% | +50.45% |
| YTD return | -94.54% | +50.43% |
| 1-year return | -76.12% | -36.40% |
| 5-year return | -99.95% | — |
| EPS (TTM) | $-21.13 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $99.75 | $8.01 |
| 52-week low | $0.78 | $0.616 |
| Distance from 52-week high | -98.46% | -78.40% |
| Average volume | 11.93M | 5.19M |
| Shares outstanding | 51.75M | 47.39M |
| Employees | 2 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYBT has outperformed SDEV by 39.7 percentage points over the past year.
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
SDEV vs ZYBT FAQ
Which is bigger, Stablecoin Development or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $81.99M compared with $79.70M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, SDEV or ZYBT?
ZYBT returned -36.40% over the past 12 months, compared with -76.12% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Stablecoin Development and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.